ReviewFrontiers in immunology2016
Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis.Medicine · 2019Pooled it
- Trial
- The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival After Chemotherapy and Allogeneic Transplantation in Mice.Annals of transplantation · 2024Article
- Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.Stem cell research & therapy · 2024Review
- Primary and secondary defects of the thymus.Immunological reviews · 2024Review
- A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders.JCI insight · 2023Article
- Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease.The Journal of clinical investigation · 2023Article
- Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine.Bioengineering (Basel, Switzerland) · 2023Review
- Common bone marrow signature in COVID-19-associated multisystem inflammatory syndrome in children: A first-wave small case series experience.Pediatric blood & cancer · 2022Article
- LNK (SH2B3) inhibition expands healthy and Fanconi anemia human hematopoietic stem and progenitor cells.Blood advances · 2022Article
- Review
- NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant development.EMBO molecular medicine · 2021Article
- Role ofFrontiers in cell and developmental biology · 2021Review
- Recent advances in our understanding of the allograft response.Faculty reviews · 2021Review
- Spatio-Temporal Bone Remodeling after Hematopoietic Stem Cell Transplantation.International journal of molecular sciences · 2020Article
- Anti-inflammatory Activity of Mesenchymal Stem Cells in λ-Carrageenan-Induced Chronic Inflammation in Rats: Reactions of the Blood System, Leukocyte-Monocyte Ratio.Inflammation · 2020Article
- Injury intensifies T cell mediated graft-versus-host disease in a humanized model of traumatic brain injury.Scientific reports · 2020Article
- Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity.Stem cell research & therapy · 2020Article
- Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells.Frontiers in cell and developmental biology · 2020Review
- The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34Stem cells (Dayton, Ohio) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bone marrow is the origin of all hematopoietic lineages and an important homing site for memory cells of the adaptive immune system. It has recently emerged as a graft-versus-host disease (GvHD) target organ after allogeneic stem cell transplantation (alloHSCT), marked by depletion of both hematopoietic progenitors and niche-forming cells. Serious effects on the restoration of hematopoietic function and immunological memory are common, especially in patients after myeloablative conditioning therapy. Cytopenia and durable immunodeficiency caused by the depletion of hematopoietic progenitors and destruction of bone marrow niches negatively influence the outcome of alloHSCT. The complex balance between immunosuppressive and cell-depleting treatments, GvHD and immune reconstitution, as well as the desirable graft-versus-tumor (GvT) effect remains a great challenge for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.